PPLPHARMA Piramal Pharma Q2 FY26 results (Jul–Sep 2025) and concall
Piramal Finance delivered a strong Q2 FY26, marked by its first earnings call following the merger of Piramal Enterprises with Piramal Finance. The company is successfully pivoting toward a retail-heavy 'Growth' book while aggressively winding down its legacy real estate exposure. With robust disbursement growth, improving operational leverage, and a clear roadmap for AI integration, management is signaling high confidence in achieving a 3% steady-state ROAUM.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue down 8.8%, net profit down 530.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 2,242 | 2,204 | 2,754 | 1,934 | 2,044 −9% |
| EBITDA | 342 | 338 | 561 | 107 | 159 −54% |
| Net profit | 23 | 4 | 154 | -82 | -99 −530% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
